XCUR · Exicure, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $0 | $0 | $0 | - | $0 | $0 | $500.0K | - | $0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $888.0K | $935.0K | $808.0K | - | $0 | $0 | $0 | - | $0 |
| SG&A | - | $1.50M | $1.51M | $2.22M | - | $1.43M | $1.24M | $1.34M | - | $2.40M |
| Total Operating Expenses | - | $2.39M | $2.51M | ($2.95M) | - | $2.57M | $1.24M | $1.34M | - | $3.32M |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | ($2.39M) | ($2.51M) | $2.95M | - | ($2.57M) | ($1.24M) | ($836.0K) | - | ($3.32M) |
| Interest Expense | - | $0 | - | - | - | $0 | $0 | - | - | $0 |
| Income Tax | - | $0 | $0 | $0 | - | $8.0K | $0 | $0 | - | $0 |
| Net Income | - | ($2.44M) | ($2.62M) | $3.01M | - | ($1.09M) | ($600.0K) | ($829.0K) | - | ($5.26M) |
| EPS - Basic | - | ($0.39) | ($0.41) | $0.49 | - | ($0.57) | ($0.35) | ($0.50) | - | ($3.05) |
| EPS - Diluted | - | ($0.39) | ($0.41) | $0.49 | - | ($0.57) | ($0.35) | ($0.50) | - | ($3.05) |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.75M | $4.44M | $7.86M | $12.51M | $12.51M | $343.0K | $528.0K | $366.0K | $816.0K | $922.0K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.69M | $1.31M | $1.84M | $1.21M | $1.03M | $1.34M | $1.58M | $1.82M | $1.63M | $865.0K |
| Current Assets | $4.62M | $5.44M | $8.65M | $11.30M | $13.67M | $2.60M | $2.08M | $1.46M | $2.02M | $3.09M |
| Total Assets | $14.04M | $15.27M | $18.74M | $20.68M | $15.06M | $10.63M | $10.69M | $10.71M | $11.58M | $12.95M |
| Current Liabilities | $3.89M | $2.77M | $4.57M | $3.89M | $3.07M | $3.65M | $3.43M | $2.66M | $2.51M | $2.22M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $10.12M | $8.34M | $9.88M | $9.30M | $8.28M | $9.09M | $9.07M | $8.50M | $8.55M | $8.45M |
| Stockholders' Equity | $3.93M | $6.93M | $8.86M | $11.38M | $6.77M | $1.54M | $1.61M | $2.21M | $3.03M | $4.50M |
| Retained Earnings | ($204.21M) | ($201.31M) | ($198.88M) | ($196.25M) | ($199.26M) | ($192.08M) | ($190.99M) | ($190.39M) | ($189.56M) | ($188.08M) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($1.60M) | - | - | - | ($450.0K) | - | - |
| Investing Cash Flow | - | - | - | ($2.09M) | - | - | - | $0 | - | - |
| Financing Cash Flow | - | - | - | $1.60M | - | - | - | $0 | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | -167.2% | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | -165.8% | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | 0.0% | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | 267.2% | - | - |
| Effective tax rate | - | - | - | 0.0% | - | - | - | - | - | - |
| Return on assets | - | -16.0% | -14.0% | 14.6% | - | -10.3% | -5.6% | -7.7% | - | -40.6% |
| Return on equity | - | -35.2% | -29.6% | 26.4% | - | -70.6% | -37.2% | -37.6% | - | -116.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.19 | 1.96 | 1.89 | 2.91 | 4.45 | 0.71 | 0.61 | 0.55 | 0.81 | 1.39 |
| Quick ratio | 1.19 | 1.96 | 1.89 | 2.91 | 4.45 | 0.71 | 0.61 | 0.55 | 0.81 | 1.39 |
| Cash ratio | 0.96 | 1.60 | 1.72 | 3.22 | 4.07 | 0.09 | 0.15 | 0.14 | 0.33 | 0.42 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.58 | 2.20 | 2.11 | 1.82 | 2.22 | 6.88 | 6.63 | 4.85 | 3.82 | 2.88 |
| Liabilities / Assets | 0.72 | 0.55 | 0.53 | 0.45 | 0.55 | 0.85 | 0.85 | 0.79 | 0.74 | 0.65 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.05 | - | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | 27.2x | - | - | - | - | - | - |
| P / B | - | 3.7x | 5.0x | 7.2x | - | 4.3x | 8.6x | 11.8x | - | 6.9x |
| P / S | - | - | - | - | - | - | - | 52.1x | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | -100.0% | - | - | - | - | - | -100.0% |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | -20.6% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | -44.1% | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 7.0% | -103.2% | - | - | 22.5% | 78.1% | 81.6% | - | 36.3% |
| Net income growth (YoY) | - | -123.4% | -336.8% | - | - | 79.2% | 89.6% | 81.2% | - | -1.9% |
| EPS growth (YoY) | - | 31.6% | -17.1% | - | - | 81.3% | 48.5% | 28.6% | - | -193.3% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -42.0% | 348.3% | 449.5% | 415.7% | 123.4% | -65.7% | -83.4% | -84.9% | -79.7% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$500.0K totalBiotechnology Segment$500.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing EXICURE against the 5 most active filers in the same SIC group.